Human Liver Models Market Worth 2.56 Billion USD by 2022

PUNE, India, April 26, 2018 /PRNewswire/ --

According to a new market research report "Human Liver Models Market by Drug Discovery Platform (Non-alcoholic Fatty Liver Organoids, Liver-on-a-chip, 2D Models, Animal Models, 3D Bioprinting), and Region (North America, Europe, Asia Pacific, Rest of the World) - Global Forecast to 2022", published by MarketsandMarkets™, the global market is expected to reach USD 2.56 Billion by 2022 from USD 1.35 Billion in 2017, at a CAGR of 13.6% during the forecast period (2017-2022). The key factors driving the growth of this market include growing focus on developing alternatives for animal testing models, significant increase in research funding and venture capital investments for the development of liver models, growing initiatives to increase awareness about liver organoids, increasing research activities on liver organoids, increasing prevalence of non-alcoholic fatty liver disease, and growing need for the early detection of drug toxicity to minimize financial losses due to late-stage drug failure.

     (Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg )

Browse 7 market data Tables and 2 Figures spread through 37 Pages and in-depth TOC on "Human Liver Models Market"

https://www.marketsandmarkets.com/Market-Reports/human-liver-model-market-171046468.html

Early buyers will receive 10% customization on this report 

Animal models accounted for the largest share of the market in 2017 

The Human Liver Models Market is segmented on the basis of type into liver organoids, liver-on-a-chip, 2D models, animal models, and 3D bioprinting. In 2017, the animal models segment accounted for the largest share of the global market. The growth in the biosimilars market is expected to boost the preclinical market as the development of biosimilars and biopharmaceuticals requires an understanding of the mechanism of action, quantification of pharmacological effects, and interpretation of toxicological data. Preclinical research also helps in securing a clear definition of targets. Moreover, as the patents for many blockbuster drugs are set to expire by 2020, the demand for biosimilars and preclinical services is likely to increase. The rising demand for preclinical services, in turn is expected to drive the demand for animal models.